These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38920090)

  • 1. Current management of giant cell arteritis and its complications.
    Galli E; Muratore F; Warrington KJ
    Curr Opin Rheumatol; 2024 Sep; 36(5):344-350. PubMed ID: 38920090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
    Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in giant cell arteritis: an update for the clinician.
    Ford JA; Gewurz D; Gewurz-Singer O
    Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
    Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
    Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of biologics in the treatment of giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
    Nielsen MK; Nielsen AW; Donskov AO; Hansen IT; Nielsen BD; Mørk C; Hauge EM; Keller KK
    Semin Arthritis Rheum; 2024 Oct; 68():152508. PubMed ID: 38981187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapses in giant cell arteritis: Updated review for clinical practice.
    Alba MA; Kermani TA; Unizony S; Murgia G; Prieto-González S; Salvarani C; Matteson EL
    Autoimmun Rev; 2024 Jun; 23(6):103580. PubMed ID: 39048072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From pathogenesis of giant cell arteritis to new therapeutic targets].
    Samson M; Bonnotte B
    Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
    Yoshifuji H
    Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
    Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
    Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant Cell Arteritis: Beyond Corticosteroids.
    Steel L; Khan A; Dasgupta B
    Drugs Aging; 2015 Aug; 32(8):591-9. PubMed ID: 26239828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis.
    Conticini E; Sota J; Falsetti P; Baldi C; Bardelli M; Bellisai F; Tosi GM; Frediani B; Cantarini L
    Mediators Inflamm; 2020; 2020():3203241. PubMed ID: 33061825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
    Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
    Miyabe C; Miyabe Y; Strle K; Kim ND; Stone JH; Luster AD; Unizony S
    Ann Rheum Dis; 2017 May; 76(5):898-905. PubMed ID: 27927642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging diagnosis tools and therapeutics for giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
    Clément J; Duffau P; Constans J; Schaeverbeke T; Viallard JF; Barcat D; Vernhes JP; Sailler L; Bonnet F
    J Rheumatol; 2021 Sep; 48(9):1435-1441. PubMed ID: 33589561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
    de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
    Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.